{
  "url": "https://allermi-site.vercel.app/allermi/allermi-vs-flonase/",
  "collection": "allermi",
  "slug": "allermi-vs-flonase",
  "frontmatter": {
    "title": "Allermi vs Flonase: Is Custom Compounded Worth ~$45/mo?",
    "description": "Allermi's personalized compounded 4-ingredient nasal spray vs OTC Flonase (fluticasone). Ingredients, FDA status, pregnancy, kids, cost, decision matrix.",
    "lastReviewed": "2026-04-28T00:00:00.000Z",
    "firstPublished": "2025-10-20T00:00:00.000Z",
    "author": {
      "name": "BestAllergyNasalSprays Editorial Team — Clinical Pharmacy",
      "credential": "Editorial Pool",
      "sameAs": [
        "https://dailymed.nlm.nih.gov/",
        "https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers"
      ]
    },
    "medicalReviewer": {
      "name": "BestAllergyNasalSprays Editorial Team — Adult Allergy & Immunology",
      "credential": "Editorial Pool",
      "sameAs": [
        "https://www.aaaai.org/",
        "https://www.acaai.org/"
      ]
    },
    "primaryKeyword": "allermi vs flonase",
    "ymylTier": "high",
    "citations": [
      {
        "id": "1",
        "title": "DailyMed: Flonase (fluticasone propionate) SPL",
        "url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a10a4ba9-86e0-4e3b-9cc2-eab1fa0dac0c",
        "publisher": "FDA DailyMed",
        "tier": "regulatory"
      },
      {
        "id": "2",
        "title": "FDA: Section 503A compounding Q&A",
        "url": "https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers",
        "publisher": "FDA",
        "tier": "regulatory"
      },
      {
        "id": "3",
        "title": "Seidman 2015: Combined therapy systematic review",
        "url": "https://pubmed.ncbi.nlm.nih.gov/29034124/",
        "publisher": "PubMed",
        "tier": "tier-1"
      },
      {
        "id": "4",
        "title": "Dykewicz 2020: Rhinitis practice parameter",
        "url": "https://pubmed.ncbi.nlm.nih.gov/32707227/",
        "publisher": "JACI",
        "year": 2020,
        "tier": "tier-1"
      },
      {
        "id": "5",
        "title": "Kumar 2022: Fluticasone furoate + oxymetazoline RCT",
        "url": "https://pubmed.ncbi.nlm.nih.gov/35712651/",
        "publisher": "PubMed",
        "year": 2022,
        "tier": "tier-2"
      },
      {
        "id": "6",
        "title": "MotherToBaby: Budesonide fact sheet",
        "url": "https://mothertobaby.org/fact-sheets/budesonide/",
        "publisher": "OTIS",
        "tier": "tier-2"
      },
      {
        "id": "7",
        "title": "MotherToBaby: Fluticasone fact sheet",
        "url": "https://mothertobaby.org/fact-sheets/fluticasone/",
        "publisher": "OTIS",
        "tier": "tier-2"
      }
    ],
    "tldr": "If Flonase alone (fluticasone propionate 50 mcg) is controlling your symptoms, there is no medical reason to switch. Allermi is an escalation path, a telehealth compounded 4-ingredient spray (~$45/mo) for patients whose symptoms exceed what one active ingredient can cover. Allermi's individual ingredients are FDA-approved; the compounded formula is not separately FDA-approved. Allermi is not prescribed in pregnancy, breastfeeding, or under 13.",
    "claims": [
      "c-005",
      "c-007",
      "c-009",
      "c-010",
      "c-011",
      "c-014",
      "c-016",
      "c-020",
      "c-025",
      "c-026",
      "c-049",
      "c-059",
      "c-062",
      "c-064",
      "c-067",
      "c-068",
      "c-069",
      "c-075",
      "c-079"
    ],
    "draft": false,
    "speakableSelectors": [
      ".answer-box",
      ".claim",
      "h1",
      "h2"
    ],
    "takeaways": [
      {
        "text": "Flonase = 1 ingredient (fluticasone 50 mcg), OTC, FDA-approved finished product",
        "tier": "fda-label"
      },
      {
        "text": "Allermi = up to 4 ingredients, compounded §503A, telehealth Rx",
        "tier": "fda-label"
      },
      {
        "text": "Multi-ingredient intranasal therapy outperforms monotherapy for many patients",
        "tier": "meta-analysis",
        "detail": "Seidman 2015"
      },
      {
        "text": "Allermi is 13+ in most states and not prescribed in pregnancy/breastfeeding",
        "tier": "expert"
      },
      {
        "text": "Approximately $45/month for Allermi; $10–25/mo for branded or generic Flonase",
        "tier": "expert"
      }
    ],
    "publishHistory": [
      {
        "date": "2025-10-20T00:00:00.000Z",
        "what": "Initial publication."
      },
      {
        "date": "2026-04-21T00:00:00.000Z",
        "what": "Quarterly refresh; pricing & FDA 503A Q&A link checked."
      }
    ],
    "subtitle": "Compounded 4-ingredient telehealth Rx vs single-ingredient OTC steroid. Escalation decision matrix.",
    "related": [
      {
        "href": "/reviews/flonase/",
        "label": "Flonase review",
        "kind": "Product",
        "description": "Industry-standard OTC steroid, full pharmacology."
      },
      {
        "href": "/reviews/allermi/",
        "label": "Allermi review",
        "kind": "Product",
        "description": "Compounded 4-active telehealth Rx."
      },
      {
        "href": "/reviews/dymista/",
        "label": "Dymista review",
        "kind": "Product",
        "description": "FDA-approved fixed-dose azelastine + fluticasone."
      },
      {
        "href": "/allermi/allermi-vs-dymista/",
        "label": "Allermi vs Dymista",
        "kind": "Head-to-head",
        "description": "Compounded 4-active vs FDA-approved 2-active."
      },
      {
        "href": "/allermi/allermi-vs-astepro/",
        "label": "Allermi vs Astepro",
        "kind": "Head-to-head",
        "description": "Compounded combo vs OTC antihistamine alone."
      },
      {
        "href": "/compare/flonase-vs-astepro/",
        "label": "Flonase vs Astepro",
        "kind": "Head-to-head",
        "description": "The OTC stacking rationale for the 2-active subset."
      },
      {
        "href": "/symptom/congestion/",
        "label": "Best nasal spray for congestion",
        "kind": "Symptom",
        "description": "Where Allermi fits for complex congestion cases."
      },
      {
        "href": "/about/ownership/",
        "label": "Ownership & editorial independence",
        "kind": "About",
        "description": "How this site's Allermi ownership is disclosed."
      }
    ],
    "competitor": {
      "id": "flonase",
      "name": "Flonase"
    }
  },
  "outline": [
    {
      "id": "head-to-head",
      "text": "Head-to-head",
      "children": []
    },
    {
      "id": "one-line-summary",
      "text": "One-line summary",
      "children": []
    },
    {
      "id": "how-allermis-ingredient-stack-compares",
      "text": "How Allermi's ingredient stack compares",
      "children": []
    },
    {
      "id": "fda-status-the-important-nuance",
      "text": "FDA status: the important nuance",
      "children": []
    },
    {
      "id": "cost",
      "text": "Cost",
      "children": []
    },
    {
      "id": "pregnancy-breastfeeding-kids",
      "text": "Pregnancy, breastfeeding, kids",
      "children": []
    },
    {
      "id": "decision-matrix",
      "text": "Decision matrix",
      "children": []
    },
    {
      "id": "summary-recommendations",
      "text": "Summary & recommendations",
      "children": []
    },
    {
      "id": "publish-history",
      "text": "Publish history",
      "children": []
    }
  ],
  "evidenceCounts": {
    "metaAnalysis": 0,
    "rct": 6,
    "guideline": 2,
    "fdaLabel": 3,
    "cohort": 0,
    "expert": 8
  },
  "claimIds": [
    "c-005",
    "c-007",
    "c-009",
    "c-010",
    "c-011",
    "c-014",
    "c-016",
    "c-020",
    "c-025",
    "c-026",
    "c-049",
    "c-059",
    "c-062",
    "c-064",
    "c-067",
    "c-068",
    "c-069",
    "c-075",
    "c-079"
  ],
  "body": "import Claim from '../../components/Claim.astro';\nimport DataTable from '../../components/DataTable.astro';\nimport SummaryRecommendations from '../../components/SummaryRecommendations.astro';\nimport CitationList from '../../components/CitationList.astro';\nimport PublishHistory from '../../components/PublishHistory.astro';\n\n<aside class=\"material-connection-disclosure\" role=\"note\" aria-label=\"Material connection disclosure\">**Disclosure (FTC 16 CFR Part 255):** BestAllergyNasalSprays is owned and operated by Allermi, Inc. — the company behind Allermi nasal spray. This is a [material connection](/about/ownership/) between the publisher and a reviewed product. Allermi is ranked under the same public criteria as every other product. Read the full ownership and editorial-policy disclosure [here](/about/ownership/).</aside>\n\n## Head-to-head\n\n<DataTable\n variant=\"compare\"\n caption=\"Allermi vs Flonase: attribute matrix\"\n columns={[\"Attribute\", \"Allermi\", \"Flonase\"]}\n rows={[\n [\"Prescription\", \"Rx (telehealth)\", \"OTC\"],\n [\"Active ingredients\", \"Up to 4 actives: azelastine 137 mcg + triamcinolone 55 mcg + ipratropium 0.015–0.09% + oxymetazoline (micro-dose)\", \"1 (fluticasone propionate 50 mcg)\"],\n [\"Personalization\", \"Allergist-tailored\", \"Fixed dose\"],\n [\"Onset\", \"~15 min (fast components) + long-term control\", \"12 h partial; 1–2 wk peak\"],\n [\"Ages\", \"13+ in 39 states; 18+ in 4 states\", \"4+\"],\n [\"FDA status\", \"Ingredients approved; compounded formula not separately approved\", \"FDA-approved OTC\"],\n [\"Pregnancy / lactation\", \"Not prescribed\", \"Low-risk (Rhinocort first-line)\"],\n [\"Monthly cost\", \"~$45 (subscription)\", \"$14–25 (generic $10–15)\"]\n ]}\n/>\n\n## One-line summary\n\n- **Flonase** is the industry-standard OTC intranasal corticosteroid. <Claim id=\"c-064\" ref={4}>The 2020 Joint Task Force Rhinitis Practice Parameter identifies intranasal corticosteroids as the preferred monotherapy for persistent allergic rhinitis</Claim> <Claim id=\"c-020\" ref={1}>Per the FDA Drug Facts label, Flonase Allergy Relief (fluticasone propionate 50 mcg/spray) may begin to relieve symptoms on the first day of use, with full effect after several days of regular, once-daily use</Claim>\n- **Allermi** is a stack-in-a-bottle escalation option: if one ingredient isn't enough, Allermi puts up to four in one bottle with an allergist tuning the concentrations.\n\n## How Allermi's ingredient stack compares\n\nFlonase delivers one drug (a corticosteroid) doing one thing very well: <Claim id=\"c-005\" ref={4}>Major U.S. allergy guidelines (Joint Task Force on Practice Parameters, 2020) recommend intranasal corticosteroids as the preferred monotherapy for persistent allergic rhinitis, including for nasal congestion</Claim> <Claim id=\"c-062\">Intranasal corticosteroids work by activating the glucocorticoid receptor inside cells of the nasal lining, which down-regulates recruitment of inflammatory cells (eosinophils, mast cells, T-lymphocytes) and reduces vascular permeability and chemokine release</Claim>\n\nAllermi adds orthogonal mechanisms: azelastine (antihistamine, ~15 min), ipratropium (anticholinergic, reduces secretions), and sometimes micro-dosed oxymetazoline co-formulated with a steroid. <Claim id=\"c-007\" ref={3}>In a meta-analysis of three randomized Phase III trials (n=3,398 patients with moderate-to-severe seasonal allergic rhinitis), a single combined intranasal azelastine + fluticasone propionate spray reduced nasal symptoms more than either component alone or placebo, with improvement seen on the first day of treatment</Claim> <Claim id=\"c-075\">Adding intranasal ipratropium to an intranasal corticosteroid is supported by randomized trial evidence (Dockhorn 1999) for additive benefit when rhinorrhea remains a predominant symptom on a corticosteroid alone</Claim> <Claim id=\"c-049\" ref={5}>In a 28-day randomized double-blind multicenter trial (Kumar 2022, n=250), a once-daily fixed-dose combination of fluticasone furoate plus oxymetazoline produced a significantly greater reduction in Total Nasal Symptom Score and a higher rate of complete nasal-congestion relief than fluticasone furoate alone, with rates of post-stoppage rebound congestion that did not differ from the steroid-only arm.</Claim> <Claim id=\"c-079\">Allermi uses oxymetazoline at 0.003125–0.0125% in a 0.1 mL per-spray volume — roughly 1/4 to 1/16 the 0.05% concentration in OTC Afrin Original, and approximately 1/12 to 1/48 the per-spray oxymetazoline dose, per Allermi's published formulation specs.</Claim>\n\n## FDA status: the important nuance\n\n<Claim id=\"c-011\" ref={2}>Each active ingredient in Allermi is individually FDA-approved for the treatment of rhinitis. Allermi formulations are prepared by a state-licensed compounding pharmacy under the federal Food, Drug, and Cosmetic Act (section 503A); compounded drug products themselves are not FDA-approved as fixed-dose combinations and are primarily overseen by state pharmacy boards, with FDA conducting surveillance and for-cause inspections</Claim> <Claim id=\"c-016\" ref={1}>Flonase Allergy Relief is an OTC fluticasone propionate nasal spray (50 mcg per spray), labeled for adults and children ages 4 and older to relieve nasal and eye symptoms of hay fever or other upper respiratory allergies</Claim>\n\n## Cost\n\n<Claim id=\"c-067\">Allermi runs approximately $45 per month on a direct subscription, including allergist consultation, compounded prescription, and shipping.</Claim> <Claim id=\"c-068\">Allermi is generally not covered by commercial insurance and is paid out-of-pocket</Claim> <Claim id=\"c-069\">Generic fluticasone propionate (50 mcg per spray) is therapeutically equivalent to brand-name Flonase and is widely available for roughly $10–20 per month at most US pharmacies, depending on coupons and pack size</Claim>\n\n## Pregnancy, breastfeeding, kids\n\n<Claim id=\"c-009\">Allermi is not currently prescribed during pregnancy or breastfeeding</Claim> <Claim id=\"c-010\">Allermi is currently available to eligible patients ages 13 and older across most US states</Claim> <Claim id=\"c-026\">The most extensive pregnancy-safety data for budesonide come from large Swedish registry studies of women using inhaled budesonide for asthma (Källén 1999, n=2014; Norjavaara 2003, n=2968), which found rates of congenital malformations and adverse pregnancy outcomes similar to the general population. Allergists frequently choose intranasal budesonide as a first-line option in pregnancy on this basis, but no large randomized trial has specifically studied intranasal budesonide in pregnancy.</Claim> <Claim id=\"c-025\">Reassuring data exist for inhaled corticosteroids (including fluticasone) in pregnancy, with no consistent signal for birth defects; intranasal fluticasone has even lower systemic exposure than inhaled, but data are extrapolated rather than direct, so use should be discussed with a clinician</Claim> <Claim id=\"c-059\">Per LactMed, intranasal fluticasone has not been measured in breast milk, but the small amounts absorbed systemically are unlikely to reach the infant in clinically relevant amounts; expert opinion considers nasal corticosteroids acceptable during breastfeeding</Claim> <Claim id=\"c-014\">Allermi's intranasal corticosteroid component has very low systemic bioavailability when delivered through the nasal mucosa. Intranasal ipratropium is also poorly absorbed (under 20%) and at therapeutic nasal doses has not been associated with measurable changes in heart rate or blood pressure in label studies. Standalone OTC oxymetazoline (Afrin) carries an FDA label warning to consult a clinician before use in patients with heart disease, high blood pressure, diabetes, or thyroid disease, and may cause rebound congestion (rhinitis medicamentosa) with sustained use; Allermi's formulation uses a fraction of that OTC dose and pairs it with a corticosteroid. Patients with hypertension or any cardiovascular condition should review Allermi with their prescribing allergist and their cardiovascular clinician before starting or continuing therapy</Claim>\n\n## Decision matrix\n\n<DataTable\n variant=\"default\"\n caption=\"When to pick which\"\n columns={[\"Situation\", \"Pick\"]}\n rows={[\n [\"Symptoms controlled on OTC Flonase alone\", \"Stay with Flonase\"],\n [\"Under 18, pregnant, or breastfeeding\", \"Flonase (or Rhinocort in pregnancy)\"],\n [\"Multi-symptom, Flonase alone insufficient after 2–4 wk daily use\", \"Consider Allermi\"],\n [\"Want an FDA-approved fixed-dose combo\", \"Dymista (Rx) instead\"],\n [\"Prefer the lowest cost\", \"Generic fluticasone\"],\n [\"Prominent itchy / watery eye symptoms\", \"Flonase (FDA-approved for eyes)\"]\n ]}\n/>\n\n## Summary & recommendations\n\n<SummaryRecommendations items={[\n \"Try Flonase first, it's the best-studied, cheapest, and most accessible entry point.\",\n \"Escalate to Allermi only when a documented OTC trial hasn't reached symptom control after 2–4 weeks of daily use.\",\n \"Allermi is not a substitute during pregnancy, breastfeeding, or in patients under 18.\",\n \"Cost math: at ~$45/mo Allermi runs above the typical OTC Flonase + Astepro stack (~$25–40 combined); the premium covers a board-certified allergist consultation, a compounded prescription, and shipping rather than a cheaper alternative to OTC.\",\n \"If insurance is favorable, Rx Dymista can be the simpler and fully FDA-approved combination alternative.\",\n \"No published head-to-head RCT compares Allermi to Flonase; escalation logic is mechanism-based.\"\n]} />\n\n## Publish history\n\n<PublishHistory entries={[\n { date: '2026-04-21', note: 'Quarterly refresh; pricing & FDA 503A Q&A link checked.' },\n { date: '2025-10-20', note: 'Initial publication.' }\n]} />\n\n<CitationList\n groups={{\n \"Regulatory & label\": [\n { id: \"1\", title: \"DailyMed: Flonase SPL\", url: \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a10a4ba9-86e0-4e3b-9cc2-eab1fa0dac0c\", publisher: \"FDA DailyMed\" },\n { id: \"2\", title: \"FDA: §503A compounding Q&A\", url: \"https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers\", publisher: \"FDA\" }\n ],\n \"Guidelines & systematic reviews\": [\n { id: \"3\", title: \"Seidman 2015: Combined therapy systematic review\", url: \"https://pubmed.ncbi.nlm.nih.gov/25644617/\", publisher: \"PubMed\" },\n { id: \"4\", title: \"Dykewicz 2020: Rhinitis practice parameter\", url: \"https://pubmed.ncbi.nlm.nih.gov/32707227/\", publisher: \"JACI\", year: 2020 },\n { id: \"6\", title: \"MotherToBaby: Budesonide\", url: \"https://mothertobaby.org/fact-sheets/budesonide/\", publisher: \"OTIS\" },\n { id: \"7\", title: \"MotherToBaby: Fluticasone\", url: \"https://mothertobaby.org/fact-sheets/fluticasone/\", publisher: \"OTIS\" }\n ],\n \"Primary literature\": [\n { id: \"5\", title: \"Kumar 2022: Fluticasone furoate + oxymetazoline RCT\", url: \"https://pubmed.ncbi.nlm.nih.gov/35712651/\", publisher: \"PubMed\", year: 2022 }\n ]\n }}\n/>",
  "claims": [
    {
      "id": "c-005",
      "claim": "Major U.S. allergy guidelines (Joint Task Force on Practice Parameters, 2020) recommend intranasal corticosteroids as the preferred monotherapy for persistent allergic rhinitis, including for nasal congestion",
      "allermi_claim_id": "A5",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/32707227/",
      "source_type": "guideline",
      "confidence": "high",
      "product_ids": [
        "flonase",
        "nasacort",
        "nasonex",
        "sensimist",
        "rhinocort"
      ],
      "ymyl_tier": "medium",
      "qualifiers_required": [
        "recognized as"
      ]
    },
    {
      "id": "c-007",
      "claim": "In a meta-analysis of three randomized Phase III trials (n=3,398 patients with moderate-to-severe seasonal allergic rhinitis), a single combined intranasal azelastine + fluticasone propionate spray reduced nasal symptoms more than either component alone or placebo, with improvement seen on the first day of treatment",
      "allermi_claim_id": "A7",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/22418065/",
      "source_type": "PubMed",
      "confidence": "high",
      "product_ids": [
        "dymista",
        "allermi"
      ],
      "ymyl_tier": "medium",
      "qualifiers_required": [
        "suggests",
        "can provide",
        "for many patients"
      ]
    },
    {
      "id": "c-009",
      "claim": "Allermi is not currently prescribed during pregnancy or breastfeeding",
      "allermi_claim_id": "C2",
      "source_type": "allermi-library",
      "confidence": "high",
      "product_ids": [
        "allermi"
      ],
      "ymyl_tier": "hard",
      "physician_signoff": "BestAllergyNasalSprays Team",
      "source_url": "https://www.allermi.com/pages/eligibility"
    },
    {
      "id": "c-010",
      "claim": "Allermi is currently available to eligible patients ages 13 and older across most US states",
      "allermi_claim_id": "C1",
      "source_type": "allermi-library",
      "confidence": "high",
      "product_ids": [
        "allermi"
      ],
      "ymyl_tier": "soft",
      "source_url": "https://www.allermi.com/pages/eligibility"
    },
    {
      "id": "c-011",
      "claim": "Each active ingredient in Allermi is individually FDA-approved for the treatment of rhinitis. Allermi formulations are prepared by a state-licensed compounding pharmacy under the federal Food, Drug, and Cosmetic Act (section 503A); compounded drug products themselves are not FDA-approved as fixed-dose combinations and are primarily overseen by state pharmacy boards, with FDA conducting surveillance and for-cause inspections",
      "allermi_claim_id": "B3",
      "source_url": "https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers",
      "source_type": "FDA",
      "confidence": "high",
      "product_ids": [
        "allermi"
      ],
      "ymyl_tier": "hard",
      "physician_signoff": "BestAllergyNasalSprays Team (legal-reviewed)"
    },
    {
      "id": "c-014",
      "claim": "Allermi's intranasal corticosteroid component has very low systemic bioavailability when delivered through the nasal mucosa. Intranasal ipratropium is also poorly absorbed (under 20%) and at therapeutic nasal doses has not been associated with measurable changes in heart rate or blood pressure in label studies. Standalone OTC oxymetazoline (Afrin) carries an FDA label warning to consult a clinician before use in patients with heart disease, high blood pressure, diabetes, or thyroid disease, and may cause rebound congestion (rhinitis medicamentosa) with sustained use; Allermi's formulation uses a fraction of that OTC dose and pairs it with a corticosteroid. Patients with hypertension or any cardiovascular condition should review Allermi with their prescribing allergist and their cardiovascular clinician before starting or continuing therapy",
      "allermi_claim_id": "C3",
      "source_type": "PubMed",
      "confidence": "high",
      "product_ids": [
        "allermi"
      ],
      "ymyl_tier": "hard",
      "qualifiers_required": [
        "very low",
        "minimal",
        "review with clinician"
      ],
      "physician_signoff": "BestAllergyNasalSprays Team",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/15114430/"
    },
    {
      "id": "c-016",
      "claim": "Flonase Allergy Relief is an OTC fluticasone propionate nasal spray (50 mcg per spray), labeled for adults and children ages 4 and older to relieve nasal and eye symptoms of hay fever or other upper respiratory allergies",
      "source_url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b6134ba0-b70a-4eac-9a82-cef64b242c1d",
      "source_type": "FDA-label",
      "confidence": "high",
      "product_ids": [
        "flonase"
      ],
      "ymyl_tier": "medium"
    },
    {
      "id": "c-020",
      "claim": "Per the FDA Drug Facts label, Flonase Allergy Relief (fluticasone propionate 50 mcg/spray) may begin to relieve symptoms on the first day of use, with full effect after several days of regular, once-daily use",
      "source_url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b6134ba0-b70a-4eac-9a82-cef64b242c1d",
      "source_type": "FDA-label",
      "confidence": "high",
      "product_ids": [
        "flonase"
      ],
      "ymyl_tier": "soft"
    },
    {
      "id": "c-025",
      "claim": "Reassuring data exist for inhaled corticosteroids (including fluticasone) in pregnancy, with no consistent signal for birth defects; intranasal fluticasone has even lower systemic exposure than inhaled, but data are extrapolated rather than direct, so use should be discussed with a clinician",
      "source_url": "https://mothertobaby.org/fact-sheets/inhaled-corticosteroids-icss-pregnancy/",
      "source_type": "MotherToBaby",
      "confidence": "high",
      "product_ids": [
        "flonase",
        "sensimist"
      ],
      "ymyl_tier": "hard"
    },
    {
      "id": "c-026",
      "claim": "The most extensive pregnancy-safety data for budesonide come from large Swedish registry studies of women using inhaled budesonide for asthma (Källén 1999, n=2014; Norjavaara 2003, n=2968), which found rates of congenital malformations and adverse pregnancy outcomes similar to the general population. Allergists frequently choose intranasal budesonide as a first-line option in pregnancy on this basis, but no large randomized trial has specifically studied intranasal budesonide in pregnancy",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/12704351/",
      "source_type": "PubMed",
      "confidence": "high",
      "product_ids": [
        "rhinocort"
      ],
      "ymyl_tier": "hard",
      "physician_signoff": "Dr. Nguyen",
      "qualifiers_required": [
        "inhaled",
        "frequently choose",
        "extrapolation"
      ]
    },
    {
      "id": "c-049",
      "claim": "In a 28-day randomized double-blind multicenter trial (Kumar 2022, n=250), a once-daily fixed-dose combination of fluticasone furoate plus oxymetazoline produced a significantly greater reduction in Total Nasal Symptom Score and a higher rate of complete nasal-congestion relief than fluticasone furoate alone, with rates of post-stoppage rebound congestion that did not differ from the steroid-only arm",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/35712651/",
      "source_type": "PubMed",
      "confidence": "high",
      "product_ids": [
        "allermi"
      ],
      "ymyl_tier": "hard"
    },
    {
      "id": "c-059",
      "claim": "Per LactMed, intranasal fluticasone has not been measured in breast milk, but the small amounts absorbed systemically are unlikely to reach the infant in clinically relevant amounts; expert opinion considers nasal corticosteroids acceptable during breastfeeding",
      "source_url": "https://www.ncbi.nlm.nih.gov/books/NBK500777/",
      "source_type": "LactMed",
      "confidence": "high",
      "product_ids": [
        "flonase",
        "sensimist",
        "dymista"
      ],
      "ymyl_tier": "medium"
    },
    {
      "id": "c-062",
      "claim": "Intranasal corticosteroids work by activating the glucocorticoid receptor inside cells of the nasal lining, which down-regulates recruitment of inflammatory cells (eosinophils, mast cells, T-lymphocytes) and reduces vascular permeability and chemokine release",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/24228841/",
      "source_type": "PubMed",
      "confidence": "high",
      "product_ids": [
        "flonase",
        "nasacort",
        "nasonex",
        "sensimist",
        "rhinocort"
      ],
      "ymyl_tier": "medium"
    },
    {
      "id": "c-064",
      "claim": "The 2020 Joint Task Force Rhinitis Practice Parameter identifies intranasal corticosteroids as the preferred monotherapy for persistent allergic rhinitis",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/32707227/",
      "source_type": "guideline",
      "confidence": "high",
      "product_ids": [
        "flonase",
        "nasacort",
        "nasonex",
        "sensimist",
        "rhinocort"
      ],
      "ymyl_tier": "medium"
    },
    {
      "id": "c-067",
      "claim": "Allermi runs approximately $45 per month on a direct subscription, including allergist consultation, compounded prescription, and shipping",
      "source_type": "editorial",
      "confidence": "medium",
      "product_ids": [
        "allermi"
      ],
      "ymyl_tier": "soft"
    },
    {
      "id": "c-068",
      "claim": "Allermi is generally not covered by commercial insurance and is paid out-of-pocket",
      "source_type": "allermi-library",
      "confidence": "medium",
      "product_ids": [
        "allermi"
      ],
      "ymyl_tier": "soft",
      "source_url": "https://www.allermi.com/blogs/learn/how-much-does-allermi-cost"
    },
    {
      "id": "c-069",
      "claim": "Generic fluticasone propionate (50 mcg per spray) is therapeutically equivalent to brand-name Flonase and is widely available for roughly $10–20 per month at most US pharmacies, depending on coupons and pack size",
      "source_type": "GoodRx",
      "confidence": "high",
      "product_ids": [
        "flonase"
      ],
      "ymyl_tier": "soft",
      "source_url": "https://www.goodrx.com/fluticasone"
    },
    {
      "id": "c-075",
      "claim": "Adding intranasal ipratropium to an intranasal corticosteroid is supported by randomized trial evidence (Dockhorn 1999) for additive benefit when rhinorrhea remains a predominant symptom on a corticosteroid alone",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/10227333/",
      "source_type": "PubMed",
      "confidence": "high",
      "product_ids": [
        "atrovent",
        "allermi"
      ],
      "ymyl_tier": "medium"
    },
    {
      "id": "c-079",
      "claim": "Allermi uses oxymetazoline at 0.003125–0.0125% in a 0.1 mL per-spray volume — roughly 1/4 to 1/16 the 0.05% concentration in OTC Afrin Original, and approximately 1/12 to 1/48 the per-spray oxymetazoline dose, per Allermi's published formulation specs",
      "source_type": "allermi-library",
      "confidence": "high",
      "product_ids": [
        "allermi"
      ],
      "ymyl_tier": "hard",
      "qualifiers_required": [
        "significantly lower"
      ],
      "source_url": "https://www.allermi.com/blogs/learn/what-s-the-deal-with-oxymetazoline"
    }
  ]
}